USA Pharma News | Healthcare News

top of page

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

ipharmaservices

16 hours ago

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

Badari Andukuri

19 hours ago

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

Badari Andukuri

1 day ago

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

ipharmaservices

Nov 23

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Nov 19

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

ipharmaservices

Feb 3

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

ipharmaservices

Jan 3

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

ipharmaservices

Apr 3, 2024

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

ipharmaservices

Mar 28, 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

ipharmaservices

Mar 4, 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

ipharmaservices

Feb 14, 2024

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

ipharmaservices

Jan 10, 2023

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

ipharmaservices

Oct 9, 2022

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

ipharmaservices

Sep 1, 2022

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

ipharmaservices

Jun 16, 2022

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

ipharmaservices

Dec 22, 2021

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

ipharmaservices

Nov 10, 2021

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

ipharmaservices

Nov 2, 2021

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

ipharmaservices

Jun 8, 2021

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

ipharmaservices

Apr 23, 2021

bottom of page